Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases.
Big Pharm is in search for the next $1 billion drug as most disease categories have been conquered. One exception is gene therapy. Gene therapy is treatments designed to replace faulty genes with healthy ones.
In 2018 Novartis acquired gene therapy player AveXis for $8.7 billion. On Feb 22nd, Roche said it will buy Spark Therapeutics (NASDAQ:ONCE) for $4.3 billion, or $114.50 per share, a premium of about 122%.
Recently, Sarepta Therapeutics (NASDAQ:SRPT) acquired a privately-held gene therapy company Myonexus. But the rumor on Wall Street is they are a takeover target.
On Friday, I noticed unusual options activity on Sarepta Therapeutics. I have never see unusual options activity so far away from current price. I mean these options are $20 and $40 away from current price.
And the Smart Money just increased their stake at the $150 strike price call options.
This can only mean that Sarepta Therapeutics is expected to be gobbled up within the next 45 days.
I don’t really follow the bio or pharmaceutical sector, but maybe I need to start.
This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.